Theriva Biologics, Inc.
corporate_fare Company Profile
Theriva Biologics, Inc. (NYSE:TOVX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for TOVX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for TOVX spans 8-K, 10-Q.
Recent high-impact activity:
- Theriva Sets 1-for-30 Reverse Split Effective December 1 to Regain NYSE American Compliance
- Theriva Holders Approve 500M Authorized Shares and 16.2M Warrant-Share Issuance
- Theriva 10-Q Reaffirms Going Concern: $8.5M Cash Lasts Only Into Q1 2027
- Theriva Posts Q3 Loss of $1.5M, Cash Runway Into Q1 2027
- Theriva Sells Ribaxamase Portfolio to Biossil for $350K Upfront, Up to $91M in Milestones
Financial Snapshot
Short Interest & Short Volume
2.74 days to coverFINRA reported short interest of 1,414,042 shares in TOVX as of the October 30, 2026 settlement, a 23.4% decrease from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 30.9% of TOVX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TOVX, detected from its recent SEC filings · based on capital-structure filings through 2026-11-18.
Authorized Shares Raised to 500 Million · Warrant Share Issuance Ratified
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →